Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-8201a in advanced colorectal cancer
NCT03384940Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2018
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in colorectal cancer (CRC), sponsored by Daiichi Sankyo Co., Ltd.. Started Feb 2018; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03384940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03384940.